{"id":"W4213073706","doi":"10.1200/jco.2022.40.6_suppl.437","title":"BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Population; Olaparib; Oncology; PARP inhibitor; Phases of clinical research; Gastroenterology; Chemotherapy; Surgery; Urology; Randomized controlled trial; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001498606,0.001541291,0.002183797,0.0005842541,0.0004722528,0.0009326991,0.001247872,0.001629572,0.005673681],"category_scores_gemma":[0.001280863,0.0008309987,0.0009134088,0.0005348348,0.00145497,0.001211373,0.0005788556,0.002996051,0.0009569205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007512241,"about_ca_system_score_gemma":0.001699246,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001142526,"about_ca_topic_score_gemma":0.002975314,"domain_scores_codex":[0.999617,0.0002155101,0.00001920723,0.000052566,0.00002574299,0.00006997543],"domain_scores_gemma":[0.9992612,0.0001577552,0.0001342472,0.00005219309,0.0000368464,0.0003577662],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.945351,0.02635483,0.001212098,0.0005196549,0.0004088986,0.00005785138,0.00009526762,0.0003449828,0.006956266,0.0001482343,0.0009656055,0.01758534],"study_design_scores_gemma":[0.9190448,0.07843482,0.001050924,0.00001118212,0.0001614654,0.00002561026,0.00001677898,0.0002669055,0.0004954209,0.00005277725,0.0004320134,0.00000719076],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894945,0.002104142,0.0005805512,0.0006758775,0.0003774982,0.004245201,0.0008414375,0.0001758396,0.001505024],"genre_scores_gemma":[0.9870771,0.00214932,0.001649418,0.0009110153,0.0002931034,0.004161762,0.000902248,0.00002428197,0.002831773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005673681,"threshold_uncertainty_score":0.01898032,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1098927837018466,"score_gpt":0.4321188489365551,"score_spread":0.3222260652347085,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}